Carcinotech is a MedTech company with expertise in manufacturing 3D-printed micro-tumours using patient-derived biopsies, primary cells, immune cells, and cancer stem cells. Our advanced offering provides a platform for rapid, ethical, and accurate drug screening, pre-clinical, and personalised medicine testing. Using patient biopsies, tissue engineering, advanced robotic manufacturing, and quality control to produce highly predictive, assay-ready printed tumours at significant throughput. This provides our clients with a “clinical biopsy” quality model, using isolated patient-specific cells and representing donor-specific cancer heterogeneity. Working with global partners, leading pharma companies, surgeons, pathologists, clinicians, and industry leaders, the goal is to accelerate drug discovery and enable the delivery of more effective cancer treatments to market. Access to Carcinotech’s robotic and automated manufacturing allows for accelerated production, with models offering high-throughput capabilities.

Media

---